Privacy Policy
Signals Blog

Contributors

Categories

10 days ago in Toronto….

The 10-year boom of the cell and gene therapy (CGT) industry has inevitably come to an end: public CGT valuations are way down, companies are settling into cash conservation mode, unrealistic salary demands are being replaced by layoffs, and the vultures circling with...

Hope vs hype and champions vs charlatans

If you are reading all or parts of this blog carnival you are probably a fan of stem cells and regenerative medicine more broadly. You probably believe this field can and will change the way medicine is practiced. But how careful are you when choosing your words to...

For advanced therapies, the sky’s the limit

Phil Vanek is responsible for technical due diligence and evaluation of potential investments, as well as guiding operational, R&D and strategic initiatives carried out at portfolio companies. An entrepreneurial and strategic international business leader, Phil...